1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
64517D495BB3A7FEF85258291006860DA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/changing-landscape-of-real-world-evidence-generation-observational-studies?opendocument
18
19opendocument
2035.173.48.224
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Data Management and Biostatics

Understanding the Changing Landscape of Real World Evidence Generation: Observational Studies

ID: 5519


Features:

6 Info Graphics

32 Data Graphics

200+ Metrics


Pages/Slides: 46


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Understanding the Changing Landscape of Real World Evidence Generation: Observational Studies"

STUDY OVERVIEW


Real World Evidence (RWE) is a key driver of formulary and reimbursement decisions by both public and private payers and is an important focus area for global regulators. Consequently, the pharmaceutical industry has been boosting internal RWE capabilities and is increasingly outsourcing to vendors specializing in RWE generation.

Observational studies, which in this research encompass five RWE study methods, are utilized by many pharma companies. Best Practices, LLC conducted this study to gain insights into current and future utilization of these five study methods (Post-authorization Safety Studies, Drug Utilization Studies, Prospective Observational Studies with HEOR Objectives, Post-authorization Efficacy studies and Medical Record Abstractions). In addition, the study presents benchmarks on the data collection methods used, the level of outsourcing used and valued vendor traits for these study types.


KEY TOPICS

  • Executive Summary: Methodology, Participants, Recommendations & Key Findings
  • Overview of Observational Studies Utilization, Data Collection Methods & Outsourcing
  • Observational Studies: Post-authorization Safety Studies, Drug Utilization Studies, Prospective Observational Studies with HEOR Objectives, Post-authorization Efficacy studies and Medical Record Abstractions

KEY METRICS

  • Note: The questions below were asked for each of the 5 types of Observational Studies examined in this study: Post-Authorization Safety Studies, Drug Utilization Studies, Prospective Observational Studies with HEOR Objectives, Post-Authorization Efficacy Studies and Medical Record Abstractions
  • What is your level of awareness/utilization regarding Post-Authorization Efficacy Studies?
  • Do you believe your usage of Post-Authorization Efficacy Studies will increase/decrease/stay same?
  • How many Post-Authorization Efficacy Studies did you conduct in the past year?
  • In 2020, how manyPost-Authorization Efficacy Studies do you anticipate doing?
  • What methods of data collection do you use for Post-Authorization Efficacy Studies?
  • In 2020, what methods of data collection will you use for Post-Authorization Efficacy Studies?
  • To what extent do you outsource Post-Authorization Efficacy Studies?
  • For Post-Authorization Efficacy Studies, what is the most critical characteristic you desire in a vendor?
  • If you have a preferred vendor for Post-Authorization Efficacy Studies, please identify them

SAMPLE KEY FINDINGS

  • Observational Studies: Respondents typically use a mix of in-house & outsourcing for 4 of 5 studies in this category: The four RWE study types in this category where most respondents use a mix of in-house and outsourcing are: Drug Utilization, Post-Authorization Efficacy, Post-Authorization Safety, and Prospective Observational w/ HEOR. Meanwhile, most respondents use only outsourcing for Medical Record Abstractions, although many use a mix too.

METHODOLOGY

This study engaged 25 leaders within 19 global organizations with deep experience in managing Real World Evidence generation at top pharmaceutical companies.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Bayer; Flexion; Vifor Pharma; Dermira; AstraZeneca; Janssen; EMD Serono; Grifols; GlaxoSmithKline ; Abbott; Novartis; Abbvie; Genzyme; Merck; UCB Pharma; Sanofi; Celldex Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.